Immuron Overview
- Status
- Public
- Employees
- 4
- Stock Symbol
- IMC
- Share Price
- $0.07
- (As of Tuesday Closing)
Immuron General Information
Description
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Contact Information
Website
www.immuron.com.au
Formerly Known As
Anadis
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
ASX
Primary Office
- Building 10
- 25-37 Chapman Street
- Blackburn North, Victoria 3131
- Australia
+61 (03) 0000 0000
Immuron Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.07 | $0.07 | $0.07 - $0.13 | $16.5M | 228M | 279K | -$0.01 |
Immuron Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 30-Jun-2021 | FY 2020 30-Jun-2020 | FY 2019 30-Jun-2019 |
|---|---|---|---|---|
| EV | (2,330) | 6,712 | 28,397 | 10,765 |
| Revenue | 267 | 109 | 1,687 | 1,707 |
| EBITDA | (3,348) | (6,215) | (1,917) | (3,326) |
| Net Income | (3,343) | (6,251) | (1,961) | (3,329) |
| Total Assets | 18,396 | 20,326 | 4,262 | 5,996 |
| Total Debt | 164 | 15 | 42 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Immuron Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Immuron‘s full profile, request access.
Request a free trialImmuron Patents
Immuron Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2986316-A1 | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | Pending | 19-Apr-2013 | 00000000000 | |
| CA-2909636-A1 | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | Pending | 19-Apr-2013 | 00000000000 | |
| US-20160083457-A1 | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | Granted | 19-Apr-2013 | 00000000000 | |
| AU-2014253685-A1 | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | Granted | 19-Apr-2013 | 00000000000 | |
| AU-2014253685-B2 | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | Active | 19-Apr-2013 | C07K16/1282 | 0 |
Immuron Executive Team (7)
Immuron Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 00000000000 | Immuron | Executive Vice Chairman | 000 0000 |
| 0000 00000000000 | Immuron | Board Member | 000 0000 |
| 00000 00000 00.0 | Immuron | Chairman | 000 0000 |
Immuron Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial